Targeted Radionuclide Therapy in Diffuse Intrinsic Brainstem Gliomas: Exploring Options Beyond the Finish Line
- PMID: 40494369
- DOI: 10.1097/RLU.0000000000005980
Targeted Radionuclide Therapy in Diffuse Intrinsic Brainstem Gliomas: Exploring Options Beyond the Finish Line
Abstract
Of the pediatric brainstem gliomas, around 80% develop in the pons, with the vast majority of pontine tumors being diffuse intrinsic brainstem gliomas (DIPG), which tend to be high grade, locally infiltrative, and have a poor prognosis. We present a 12-year-old girl diagnosed with DIPG in July 2022, who received 60 Gy, 30 fractions of radical radiotherapy over 6 weeks, followed by temozolomide. With residual disease, the patient was referred to our department for the possibility of radiotheranostics. She underwent 68Ga PSMA PET/CT, which revealed tracer accumulation in the pontine mass and was subsequently given 2 cycles of Lu-177 PSMA 617 and 1 cycle of Ac-225 PSMA 617 therapy.
Keywords: DIPG; PRRT; pediatric tumors.
Copyright © 2025 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
Conflicts of interest and sources of funding: none declared.
References
-
- Vanan MI, Eisenstat DD. DIPG in children—what can we learn from the past? Front Oncol. 2015;5:237.
-
- Cooney T, Lane A, Bartels U, Bouffet E, et al. Contemporary survival endpoints: an international diffuse intrinsic pontine glioma registry study. Neuro Oncol. 2017;19:1279–1280.
-
- Zhang M, Xiao X, Gu G, et al. Role of neuronavigation in the surgical management of brainstem gliomas. Front Oncol. 2023;13:1159230.
-
- Gwak HS, Park HJ. Developing chemotherapy for diffuse pontine intrinsic gliomas (DIPG). Crit Rev Oncol Hematol. 2017;120:111–119.
-
- Gallitto M, Lazarev S, Wasserman I, et al. Role of radiation therapy in the management of diffuse intrinsic pontine glioma: a systematic review. Adv Radiat Oncol. 2019;4:520–531.
LinkOut - more resources
Full Text Sources
Miscellaneous
